Table of Contents

Subunit Composition of Functional Nicotinic Receptors in Dopaminergic Neurons Investigated with Knock-Out Mice

  1. Jean-Pierre Changeux1
  1. 1Laboratoire de Neurobiologie Moléculaire, Centre National de la Recherche Scientifique Unité de Recherche Associée 2182 “Récepteurs et Cognition,” Institut Pasteur, 75724 Paris Cedex 15, France, 2Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Section of Cellular and Molecular Pharmacology, Department of Medical Pharmacology and Center of Excellence on Neurodegenerative Diseases, University of Milan, 20129 Milan, Italy, 3Laboratoire de Neuropharmacologie Equipe Associée-Ministere de l'Education Nationale de la Recherche et de la Technologie, Faculté de Pharmacie Institut Fédératif de Recherche-Institut de Signalisation at Innovation Thérapeutique, Institut de Signalisation et d'Innovation Thérapeutique, Université Paris-Sud, F92296 Châtenay-Malabry cedex, France, and 4Departments of Psychiatry and Biology, University of Utah, Salt Lake City, Utah 84112

Abstract

Nicotinic acetylcholine receptors (nAChRs) expressed by dopaminergic (DA) neurons have long been considered as potential therapeutic targets for the treatment of several neuropsychiatric diseases, including nicotine and cocaine addiction or Parkinson's disease. However, DA neurons express mRNAs coding for most, if not all, neuronal nAChR subunits, and the subunit composition of functional nAChRs has been difficult to establish. Immunoprecipitation experiments performed on mouse striatal extracts allowed us to identify three main types of heteromeric nAChRs (α4β2*, α6β2*, and α4α6β2*) in DA terminal fields. The functional relevance of these subtypes was then examined by studying nicotine-induced DA release in striatal synaptosomes and recording ACh-elicited currents in DA neurons fromα4, α6, α4α6, and β2 knock-out mice. Our results establish that α6β2* nAChRs are functional and sensitive to α-conotoxin MII inhibition. These receptors are mainly located on DA terminals and consistently do not contribute to DA release induced by systemic nicotine administration, as evidenced by in vivo microdialysis. In contrast, (nonα6)α4β2* nAChRs represent the majority of functional heteromeric nAChRs on DA neuronal soma. Thus, whereas a combination of α6β2* and α4β2* nAChRs may mediate the endogenous cholinergic modulation of DA release at the terminal level, somato-dendritic (nonα6)α4β2* nAChRs most likely contribute to nicotine reinforcement.

  • Received March 31, 2003.
  • Revision received June 24, 2003.
  • Accepted July 7, 2003.